ArticleCancer cell international2025
Investigating the potential role of miR-451a as a tumor suppressor in immunogenic cell death induction and dendritic cell maturation in colorectal cancer cell lines.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Tyrosine-Peptide Analog Modulates Extracellular Vesicles miRNAs Cargo from Mesenchymal Stem/Stromal and Cancer Cells to Drive Immunoregeneration and Tumor Suppression.Biomolecules · 2026Article
- Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a leading cause of cancer-related mortality, as conventional therapies are frequently hampered by treatment resistance and the presence of an immunosuppressive tumor microenvironment (TME). Immunotherapy, particularly strategies based on immunogenic cell death (ICD) induction can activate the TME by enhancing tumor immunogenicity and promoting T cell infiltration, potentially improving the efficacy of cancer immunotherapies in CRC. This study investigates the potential of miR-451a as a tumor suppressor in the release of ICD associated damage-associated molecular patterns in CRC cell lines and maturation of dendritic cells (DCs).
methodsHuman CRC cell lines (SW48, SW1116, SW480, and Caco-2) were treated with oxaliplatin alone or transfected with the hsa-miR-451a mimic, scrambled miRNA, or a combination of the hsa-miR-451a mimic and oxaliplatin for 48 h. Cell viability was measured using MTT assays, and apoptosis was assessed through annexin V and PI staining. Flow cytometry was employed to evaluate calreticulin (CRT) levels on the cell surface and to analyze the percentages of CD11c + CD86 + CD80 + mature DCs. Additionally, ATP levels were quantified using a luminescence assay, and HMGB1 levels were measured by ELISA.
resultsOur results demonstrated that the overexpression of miR-451a significantly increased apoptosis and CRT surface exposure in all four CRC cell lines, like the effects observed with oxaliplatin, when compared to both the control and scrambled miRNA groups (P < 0.05, P < 0.01, P < 0.001, and P < 0.0001). However, the combination of miR-451a with oxaliplatin did not yield synergistic effects across all cell lines. Additionally, the ability of miR-451a to increase extracellular ATP and HMGB1 levels, as well as its effect on DC maturation, varied among cell lines.
conclusionsThe findings of this study presents novel insights into the potential role of miR-451a as a tumor-suppressive agent in CRC. By examining its effect on ICD across four different CRC cell lines, we provide a comprehensive analysis of its impact on both tumor cells and the immune system. Our results suggest that miR-451a induce certain characteristics of the ICD response, which vary depending on the cellular context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.